Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) insider John F. Neylan sold 1,445 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $7.14, for a total transaction of $10,317.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
John F. Neylan also recently made the following trade(s):
- On Monday, July 24th, John F. Neylan sold 1,214 shares of Keryx Biopharmaceuticals stock. The shares were sold at an average price of $7.27, for a total transaction of $8,825.78.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) opened at 6.42 on Friday. The stock’s market capitalization is $762.38 million. The company’s 50-day moving average is $7.24 and its 200-day moving average is $6.15. Keryx Biopharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.60. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. During the same quarter last year, the company earned ($0.42) EPS. The business’s revenue was up 62.4% compared to the same quarter last year. Equities research analysts forecast that Keryx Biopharmaceuticals, Inc. will post ($1.23) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Insider Sells $10,317.30 in Stock” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2017/08/12/insider-selling-keryx-biopharmaceuticals-inc-nasdaqkerx-insider-sells-1445-shares-of-stock-updated.html.
Several institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. increased its position in Keryx Biopharmaceuticals by 4.2% in the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares during the period. OZ Management LP bought a new position in Keryx Biopharmaceuticals during the first quarter valued at about $109,000. Usca Ria LLC bought a new position in Keryx Biopharmaceuticals during the first quarter valued at about $128,000. Jane Street Group LLC bought a new position in Keryx Biopharmaceuticals during the first quarter valued at about $141,000. Finally, Legal & General Group Plc increased its position in Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares during the period. Hedge funds and other institutional investors own 57.06% of the company’s stock.
Several equities research analysts have recently commented on the stock. ValuEngine raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. Cowen and Company reaffirmed a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 target price (up from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $7.48.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
What are top analysts saying about Keryx Biopharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Keryx Biopharmaceuticals Inc. and related companies.